Online inquiry

IVTScrip™ mRNA-Human ADORA2B, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK8961MR)

This product GTTS-WK8961MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ADORA2B protein. This product can be used in Astrocyte-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_000676.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 136
UniProt ID P29275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ADORA2B, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK8961MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK23841MR IVTScrip™ mRNA-Human ARL4A, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ARL4A
GTTS-WK17965MR IVTScrip™ mRNA-Human ANXA7, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ANXA7
GTTS-WK10094MR IVTScrip™ mRNA-Human ADAM28, (Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ADAM28
GTTS-WK26892MR IVTScrip™ mRNA-Human ASAP2, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ASAP2
GTTS-WK9197MR IVTScrip™ mRNA-Human ADAM9, (Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ADAM9
GTTS-WK23219MR IVTScrip™ mRNA-Human ARHGEF39, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARHGEF39
GTTS-WK20017MR IVTScrip™ mRNA-Human ANKRD31, (Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ANKRD31
GTTS-WK25081MR IVTScrip™ mRNA-Human ARRDC3-AS1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARRDC3-AS1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW